文献速递神经肿瘤

多组学解析脑膜瘤预后:巨噬细胞多样性、免疫-CNV互作及SPP1靶向新策略

Decoding meningioma prognosis with multi-omics: macrophage diversity, immune-CNV interplay, and novel SPP1-targeted strategies.
PubMed 文献 · J Neurooncol · 2025-06-16

该研究对302对配对脑膜瘤样本进行DNA甲基化与bulk RNA-seq整合多组学聚类,识别出五种分子类型(CS1-CS5),各具不同复发风险、生存、CNV景观和免疫微环境。单细胞RNA-seq验证CNV发现并解卷积类型特异性巨噬细胞群,发现SPP1上调与CS1不良预后相关、下调可能促成CS4较好结局,提示靶向SPP1重编程巨噬细胞用于未来分型导向治疗。

要点

  • 基于DNAme与RNA-seq整合聚类可将脑膜瘤分为CS1-CS5五种分子类型,各型复发风险与免疫微环境不同。
  • CS4以高巨噬细胞浸润为特征,CS5呈免疫荒漠特征,染色体22缺失与免疫浸润相关。
  • SPP1上调与CS1不良预后相关,下调可能促成CS4较好结局,靶向SPP1具巨噬细胞重编程潜力。

核心结论

  • 脑膜瘤预后分层可刻画巨噬细胞功能异质性与CNV驱动的免疫微环境差异。
  • SPP1是巨噬细胞功能的关键调控因子,有望成为侵袭性分子类型的治疗候选靶点。

研究设计与样本

  • 对302对配对脑膜瘤样本的DNAme与bulk RNA-seq数据进行整合多组学聚类。
  • 利用单细胞RNA-seq验证CNV发现,并以SCISSOR解卷积类型特异性巨噬细胞群。
  • 采用scRank评估候选基因以识别治疗靶点。

主要发现

  • 识别出五种脑膜瘤分子类型(CS1-CS5),各型复发风险、生存、CNV景观与免疫微环境不同:增殖型CS1、代谢型CS2、混合型CS3、免疫富集型CS4、NF2野生型CS5。
  • CS4以高巨噬细胞浸润为特征,CS5呈免疫荒漠特征。
  • 类型特异性CNV谱显示染色体22缺失与免疫浸润相关。
  • 以SPP1为中心的基因网络提示其在巨噬细胞可塑性中的调控作用。
  • SPP1上调与CS1不良预后相关,下调可能促成CS4较好结局。

关键数值与推荐

  • 药物敏感性分析提示靶向SPP1用于巨噬细胞重编程具潜力,可服务于未来分型导向治疗。

临床怎么用

  • 可依据CS1-CS5分子分型评估脑膜瘤复发风险与免疫微环境特征。
  • 对免疫富集型CS4与免疫荒漠型CS5可考虑不同的免疫相关治疗策略。
  • SPP1可作为侵袭性分子类型(如CS1)的候选治疗靶点进行后续验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Meningiomas exhibit significant tumor heterogeneity leading to diverse prognosis of patients. While DNA methylation (DNAme)-based classification has shown good performance in subtyping of meningiomas, single-cell transcriptomics offer an opportunity to further explore cell population activity. Understanding the functional states of macrophage populations is especially critical in meningiomas, given their established roles in tumor progression and therapeutic response. METHODS: We performed integrated multi-omics clustering of DNAme and bulk RNA-seq data from 302 paired meningioma samples. This identified molecular types characterized by distinct survival, copy number variation (CNV), immune infiltration, and pathway enrichment profiles. Single-cell RNA-seq (scRNA-seq) validated CNV findings and enabled deconvolution of type-specific macrophage populations using SCISSOR, while scRank assessed candidate genes to identify therapeutic targets. RESULTS: We identified five meningioma molecular types (CS1-CS5) with distinct recurrence risks, survival, CNV landscapes, and immune microenvironments: Proliferative (CS1), Metabolic (CS2), Mixed (CS3), Immune-Enriched (CS4), and NF2-Wild-Type (CS5). CS4 was featured by high macrophage infiltration, while CS5 showed immune-desert characteristics. Type-specific CNV profiles showed chromosome 22 deletions relating to immune infiltration, and SPP1-centered gene networks highlighted its regulatory role in macrophage plasticity. Particularly, SPP1 upregulation associated with poor prognosis in CS1 and downregulation likely contributed to better outcomes in CS4. Drug sensitivity analyses identified the potential of targeting SPP1 for macrophage reprogramming in future type-directed therapies. CONCLUSION: Our meningioma prognostic stratification characterized macrophage functional heterogeneity and CNV-driven immune microenvironment disparities. We found SPP1 as a critical regulator for macrophage function and offering a promising candidate for future treatment to target in an aggressive molecular type.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Fan H, Li X, Zhao Y, et al. Decoding meningioma prognosis with multi-omics: macrophage diversity, immune-CNV interplay, and novel SPP1-targeted strategies. J Neurooncol. 2025. PMID: 40522564. doi:10.1007/s11060-025-05116-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。